These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38949295)

  • 21. Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes.
    Alexopoulos AS; Parish A; Olsen M; Batch BC; Moylan CA; Crowley MJ
    Endocr Pract; 2024 Jul; 30(7):663-669. PubMed ID: 38697305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.
    Liu CH; Chang YP; Fang YJ; Cheng PN; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
    J Gastroenterol; 2024 Jul; 59(7):609-620. PubMed ID: 38613690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
    J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Esparham A; Shoar S; Mehri A; Khorgami Z; Modukuru VR
    Obes Surg; 2024 Jul; 34(7):2338-2346. PubMed ID: 38662250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa.
    Younossi ZM; Golabi P; Paik J; Owrangi S; Yilmaz Y; El-Kassas M; Alswat K; Alqahtani SA
    Liver Int; 2024 Apr; 44(4):1061-1070. PubMed ID: 38305642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1950-1956. PubMed ID: 38740513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
    Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
    Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.
    Amjad W; Jiang ZG; Lai M
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1038-1045. PubMed ID: 38829950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
    Meroni M; Longo M; Dongiovanni P
    Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2029-2038. PubMed ID: 38330228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.
    Anson M; Zhao SS; Essa H; Austin P; Ibarburu GH; Lip GYH; Alam U
    Clin Ther; 2023 Dec; 45(12):1259-1265. PubMed ID: 37648574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.
    Henney AE; Riley DR; Hydes TJ; Anson M; Ibarburu GH; Zhao SS; Cuthbertson DJ; Alam U
    Liver Int; 2024 Sep; ():. PubMed ID: 39221811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis.
    Ugwendum D; Mohamed M; Al-Ajlouni YA; Nso N; Njei B
    Cureus; 2024 Jun; 16(6):e62441. PubMed ID: 39011212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.